The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net (loss) income from operations | -10,860 | 15,191 | 16,748 | 16,639 |
| Shares received in settlement of litigation | - | 0 | 0 | 0 |
| Loss on extinguishment of debt | - | 0 | 0 | 0 |
| Depreciation and amortization | -10,044 | - | 5,290 | 6,371 |
| Credit loss expense | 1,464 | 3,366 | 2,056 | 1,093 |
| Non-cash lease expenses | 330 | 325 | 318 | 619 |
| Share-based compensation | -1,696 | 2,463 | 4,919 | 9,014 |
| Depreciation and amortization | - | 14,881 | - | - |
| Deferred income taxes | 4,531 | -2,051 | -5,751 | -908 |
| Other | 118 | 98 | 249 | 294 |
| Accounts receivable | -28,209 | 887 | 11,014 | 14,493 |
| Inventory | 889 | -1,162 | 1,612 | 1,083 |
| Prepaid expenses | - | - | -615 | -155 |
| Other assets | -2,012 | 3,117 | 3,440 | 2,261 |
| Accounts payable | 1,936 | -1,586 | 2,913 | 792 |
| Accrued compensation | -15,706 | 3,415 | 6,362 | -791 |
| Accrued expenses | -375 | -1,441 | 284 | 3,528 |
| Other liabilities | 250 | 1,466 | -110 | -1,067 |
| Net cash flows from operating activities of continuing operations | - | 24,956 | 29,329 | 19,718 |
| Net cash flows used in operating activities of discontinued operations | - | 0 | 0 | 0 |
| Net cash flows provided by operating activities | 1,879 | 24,956 | 29,329 | 19,718 |
| Cash paid for acquisitions | 5,000 | 0 | 3,064 | 700 |
| Purchases of equipment | 570 | 285 | 192 | 556 |
| Patent application costs | 33 | - | 2 | 37 |
| Other investments | - | 89 | 2,000 | - |
| Prepayment premium on previous term loan | - | 0 | 0 | 0 |
| Net cash flows used in investing activities | -5,642 | -335 | -5,258 | -1,293 |
| Deferred financing cost | - | 0 | 0 | 0 |
| Repayment of previous term loan | - | 0 | 0 | 0 |
| Repayment of citizens revolving credit facility | - | 0 | 0 | 0 |
| Proceeds from exercise of stock options | - | 0 | 0 | 0 |
| Proceeds from citizens revolving credit facility | - | 0 | 0 | 0 |
| Proceeds from citizens term loan | - | 0 | 0 | 0 |
| Principal payments on finance lease | - | - | 0 | 0 |
| Stock repurchased for tax withholdings on vesting of restricted stock | 1,901 | 51 | 83 | 2,984 |
| Repurchase of series b preferred shares | - | 0 | - | - |
| Principal payments on citizens term loan facility | -375 | 1,750 | -250 | -500 |
| Other | - | 0 | - | - |
| Cash paid for profit share payment (note 12) | 309 | 282 | 524 | 488 |
| Net cash flows used in financing activities | -2,585 | -583 | -857 | -3,972 |
| Net change in cash | -6,348 | 24,038 | 23,214 | 14,453 |
| Cash and cash equivalents, beginning of period | 166,121 | 142,083 | 104,416 | - |
| Cash and cash equivalents, end of period | 159,773 | 166,121 | 142,083 | - |
MIMEDX GROUP, INC. (MDXG)
MIMEDX GROUP, INC. (MDXG)